Pipeline Review for Guillain-Barre Syndrome - H1 2020 - ResearchAndMarkets.com

The "Guillain-Barre Syndrome - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

This Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 2, 1 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Guillain-Barre Syndrome - Overview
• Guillain-Barre Syndrome - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Guillain-Barre Syndrome - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Guillain-Barre Syndrome - Companies Involved in Therapeutics Development
• Guillain-Barre Syndrome - Drug Profiles
• Guillain-Barre Syndrome - Dormant Projects
• Guillain-Barre Syndrome - Product Development Milestones
• Featured News & Press Releases

Companies Mentioned

• Akari Therapeutics Plc
• Annexon Inc
• Cellenkos Inc
• Complement Pharma BV
• CuraVac Inc
• Hansa Biopharma AB
• Vitality Biopharma Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/12v4aq

View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005228/en/